A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting. The COSMiC Prospective Prostate Cancer Registry
The purpose of this study is to temporally evaluate the impact of abiraterone acetate
(ZYTIGA) therapy on Patient Reported Outcomes (PROs) and on clinical outcomes in the
chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) population. Safety
data, levels of health care resource utilization associated with abiraterone acetate
(ZYTIGA) therapy will also be prospectively collected and analyzed.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society